Alamy/SOPA Images Limited
Abiomed’s PROTECT Trial
Abiomed holds the distinction of keeping medtech in the discussion when it came down to the pandemic. While chatter circled around diagnostics and vaccines, the Danvers, MA-based company was able to win emergency use authorization for the Impella RP to include patients suffering from COVID-19 related heart failure or decompensation, including pulmonary embolism.
The firm returned to form at TCT with the PROTECT III study showing PROTECT II-like patients (those that would have qualified for PROTECT II) who underwent high-risk PCI had 90-day major adverse cardiac and cerebral vascular event (MACCE) rates of 15.1% (n=390) vs. 21.9% in the Impella arm of the PROTECT II study, a relative risk reduction of 31% (p=0.037).